SNN - Smith & Nephew sells 2 wound-healing cell therapies to Healiva

Switzerland-based Healiva acquired two cell therapy assets from U.K.-based Smith & Nephew (NYSE:SNN) to bolster its portfolio of wounds care products. Financial details were not disclosed. Healiva said the the first asset, EpiDex is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). The company said EpiDex was previously approved in the Swiss market, and Healiva's acquisition of the complete product dossier should enable a market re-launch of EpiDex. The second asset, now named healiva002, is an allogeneic cell therapy that has previously shown efficacy in healing VLUs that are resistant to standard treatments, Healiva's said in a June 1 press release.

For further details see:

Smith & Nephew sells 2 wound-healing cell therapies to Healiva